Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Valo Health Appoints Accomplished Executive Peggy Dalicandro as Vice President, Head of Human Resources

Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

Valo Health Announces Topline Results from Phase 2 SPECTRA Study of OPL-0401 in Patients with Diabetic Retinopathy

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy

Valo Health Announces Changes to its Board of Directors and Leadership Team

Lisa P. Young Appointed to Valo’s Board of Directors

Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence

Valo Health to Participate in the Jefferies Global Healthcare Conference

Valo Health to Participate in Upcoming Conferences and Events

Valo Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

Valo Health - FDA Collaborative Study in Human Cardiac Tissues Demonstrates Potential to Predict Clinical Efficacy of Cardiac Contractility Modulation Devices to Treat Heart Failure

Valo Health To Participate in Piper Sandler's 34th Annual Healthcare Conference

Valo's David Berry to Deliver Keynote at Founders Network's fnSummit 2022

KSM Research and Innovation Center and Valo Health Announce First-of-Its-Kind Multiyear Collaboration to Spearhead Preventative Care and Personalized Medicine for Patients

Valo Health to Participate in UBS Biotechnology Virtual Private Company Symposium

Valo Health To Participate in Citi's 17th Annual BioPharma Conference

Valo Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy

Valo Health to Participate in June Conferences and Events

Valo Health Announces Publication of the Journal of Clinical Investigation of a New Therapeutic Approach to Improve CD8+ T Cell Function

Valo Health to Present at UBS Global Healthcare Conference 2022